SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending after announcing a 75 million-share public offering to raise approximately $1.5 billion, sparking a sharp decline as investors react to the dilution. While community sentiment is heavily polarized, the primary debate focuses on whether this capital raise is a necessary move to unlock government loan funding for factory expansion or a poorly timed decision that undermines recent stock momentum.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is facing heightened volatility and selling pressure following a patent infringement lawsuit filed by Wolfspeed, which has triggered community debate over the company's long-term competitive position and legal risks. Investors are sharply divided between those viewing the pullback as a buying opportunity based on the stock's role in AI data center power infrastructure and others cautioning against overvaluation and potential dilution.

Penguin Solutions, Inc. engages in designing, building, and managing enterprise solutions. It operates through the following segments: Advanced Computing, Integrated Memory, and Optimized LED. The Advanced Computing segment offers platform solutions and services for artificial intelligence, high-performance computing, machine learning, advanced modeling, and the internet of things. The Integrated Memory refers to integrated memory solutions through the design and development. The Optimized LED segment comprises a broad portfolio of application-optimized LEDs. The company was founded in 1988 and is headquartered in Fremont, CA.

Penguin Solutions Inc.

Penguin Solutions is gaining significant attention following a strong earnings beat and raised guidance, fueled by robust demand for its AI infrastructure and integrated memory solutions. The community is actively debating the stock's potential as an AI factory partner versus concerns regarding its memory-focused business model and potential share dilution.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is actively trending as traders weigh the impact of renewed geopolitical tensions in the Strait of Hormuz against fluctuating ceasefire signals. Community discussion is heavily focused on the stock's sensitivity to oil supply disruptions, with many bulls interpreting recent price volatility as a long-term accumulation opportunity despite ongoing market uncertainty.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending as investors react to a significant share offering aimed at funding manufacturing expansion for the growing AI data center power market. While some in the community view the capital raise as a necessary step to scale operations and meet rising demand, many retail shareholders are expressing frustration over the dilutive impact on their positions and the company's long-term performance history.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to bullish sentiment surrounding its obesity pipeline, with community members actively discussing a potential partnership or buyout as the company approaches key Phase 3 milestones and maintenance data readouts. Investors are closely monitoring strong price action and order flow, which many interpret as strategic accumulation by institutions anticipating positive clinical catalysts later this year.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is surging following positive Phase 3 clinical data for its COMP360 psilocybin treatment, which demonstrates rapid and durable efficacy in patients with treatment-resistant depression. The community is actively discussing the stock's potential for FDA approval and eventual buyout, with many traders emphasizing the company's strong cash position and its role as a first-mover in the high-stakes psychedelic medicine sector.

Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Vertex Pharmaceuticals, Inc.

Vertex Pharmaceuticals is trending following the major ten billion dollar all-cash acquisition of Crinetics Pharmaceuticals, a strategic move that significantly expands its pipeline into the rare endocrine and obesity landscape. Community discussion is heavily focused on how this deal serves as a broader validation for the sector's growth potential while prompting investors to reassess the company's long-term valuation alongside its existing robust clinical pipeline.

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The firm's product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. It is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is trending after Vertex Pharmaceuticals announced a definitive agreement to acquire the company for $10 billion in an all-cash deal. The community is actively discussing the massive valuation premium and the strategic validation the acquisition provides for the broader rare endocrine and obesity therapeutic landscape.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

BABA is facing downward pressure amid reports of internal security bans regarding foreign AI coding tools and ongoing legal headwinds, leading to intense community debate between those viewing it as a distressed value opportunity and others calling it a permanent value trap. The stock remains highly volatile as traders focus on its oversold RSI levels and institutional rebalancing, with many investors debating whether its current technical weakness marks a bottom or a continued downtrend.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CAPR  Approval could come earlier in nice bold print in the legal filing :) Cant see them not winning this suit.

Lets go!

Patate Chaude

David Fowler

Morten Skov Schiellerup

UncleB13

Veg Green

Gray Wolf

Chris Gold

Groggok

Pork fried rice

idea guy

Sammy B

DT24

CAPRise

StockTwits Web

StockTwits For Android 

Capricor Therapeutics Inc

  Approval could come earlier in nice bold print in the legal filing :) Cant see them not winning this suit.

Lets go!

@erpy “mutual mistake”?? A pretty high bar if their lawyers drew up the agreement.

StockTwits for iOS

 “mutual mistake”?? A pretty high bar if their lawyers drew up the agreement.

Herb novogroski

@erpy wait this ain&#39;t good. They are saying basically islya too expensive and no one would cover it ?    I thought payors already said it would be covered

 wait this ain't good. They are saying basically islya too expensive and no one would cover it ?    I thought payors already said it would be covered

Joe momma

@Novo1 Im no lawyer but an agreement which requires you to sell a product such that you can&#39;t recover even your cost , and prevents coverage by insurance for the patients sounds like a FATAL flaw agreement to me.

Jmho

 Im no lawyer but an agreement which requires you to sell a product such that you can't recover even your cost , and prevents coverage by insurance for the patients sounds like a FATAL flaw agreement to me.

Jmho

@Machman1 Thats why capicore is arguing that the distribution agreement has a FATAL flaw.

They wouldnt even be able to recover their cost to develop, manufacture snd distrubute as I read it and it wouldnt be covered by insurance.

Their argument seems fair and reasonable to me but im no lawyer.

 Thats why capicore is arguing that the distribution agreement has a FATAL flaw.

They wouldnt even be able to recover their cost to develop, manufacture snd distrubute as I read it and it wouldnt be covered by insurance.

Their argument seems fair and reasonable to me but im no lawyer.

@erpy I’m a lawyer and never heard of a “fatal” flaw agreement. “Mutual mistake”, yes! But, where is the mistake?

 I’m a lawyer and never heard of a “fatal” flaw agreement. “Mutual mistake”, yes! But, where is the mistake?

@erpy but isn&#39;t it just as much caprs fault for agreeing to these terms ?

 but isn't it just as much caprs fault for agreeing to these terms ?

@Machman1 She is protecting us all my friend.

@erpy is NS Pharma a party to the agreement?

@erpy recession and/or renegotiation! Probably recession based on “mutual mistake”

 recession and/or renegotiation! Probably recession based on “mutual mistake”

@Novo1  probably im no expert but thats a reasonable perspective to me

  probably im no expert but thats a reasonable perspective to me

@erpy remember, burden of proof is on $CAPR!!

@Novo1 Shouldnt be hard to prove how much it has cost them to develop, approve and manufacture the drug.   Selling it for less then that without a reasonable profit would be a ridiculous price strategy.  Not allowing typical dmd patients access to the life saving drug, and having it  covered by insurance, especially on a drug  approved by the fda, wouldnt seem reasonable to any jury I ever sat on.  Seems common sense to me.  Jmho

 Shouldnt be hard to prove how much it has cost them to develop, approve and manufacture the drug.   Selling it for less then that without a reasonable profit would be a ridiculous price strategy.  Not allowing typical dmd patients access to the life saving drug, and having it  covered by insurance, especially on a drug  approved by the fda, wouldnt seem reasonable to any jury I ever sat on.  Seems common sense to me.  Jmho